Colorectal cancer(CRC)is the third most common cancer and the leading cause of cancer death globally.Resistance to therapy is a challenge for CRC treatment.Mesenchymal stem cells(MSCs)have become one of the furthermos...Colorectal cancer(CRC)is the third most common cancer and the leading cause of cancer death globally.Resistance to therapy is a challenge for CRC treatment.Mesenchymal stem cells(MSCs)have become one of the furthermost effective approaches for tumor treatment due to their specific feature;however,their therapeutic function is controversial.Recently,extracellular vesicles(EVs)derived from MSCs(MSCs-EVs)have attracted extensive research attention due to their promising role in CRC treatment.EVs are cell-derived vesicles that transfer different biomolecules between cells,contributing to intracellular communication.MSCs-EVs can suppress CRC by delivering therapeutic agents to tumor cells.Several studies indicate that MSCs-EVs can serve as a drug delivery system for the treatment of different cancers.Various methods are used to modify(engineer)MSCs-EVs for loading therapeutic agents.Modified MSCs-EVs have improved specificity,targeting ability,and immunogenicity compared to synthetic carriers.Furthermore,CRC-EVs participate in regulating different cells,such as immune cells,fibroblasts,and endothelial cells,promoting tumorigenesis.MSCs-EVs-based therapy indicates a high potential in the treatment of cancer;however,the majority of studies have been conducted in the pre-clinical,and their clinical applications need further scrutiny.In this review,we describe the biogenesis of EVs,focusing on the effect of MSCs-EVs on CRC cells and CRC-derived EVs on other cells.Furthermore,MSCs-EVs as a drug delivery system for cancers is also reviewed,and perspectives regarding the therapeutic application of MSCs-EVs are discussed.展开更多
文摘Colorectal cancer(CRC)is the third most common cancer and the leading cause of cancer death globally.Resistance to therapy is a challenge for CRC treatment.Mesenchymal stem cells(MSCs)have become one of the furthermost effective approaches for tumor treatment due to their specific feature;however,their therapeutic function is controversial.Recently,extracellular vesicles(EVs)derived from MSCs(MSCs-EVs)have attracted extensive research attention due to their promising role in CRC treatment.EVs are cell-derived vesicles that transfer different biomolecules between cells,contributing to intracellular communication.MSCs-EVs can suppress CRC by delivering therapeutic agents to tumor cells.Several studies indicate that MSCs-EVs can serve as a drug delivery system for the treatment of different cancers.Various methods are used to modify(engineer)MSCs-EVs for loading therapeutic agents.Modified MSCs-EVs have improved specificity,targeting ability,and immunogenicity compared to synthetic carriers.Furthermore,CRC-EVs participate in regulating different cells,such as immune cells,fibroblasts,and endothelial cells,promoting tumorigenesis.MSCs-EVs-based therapy indicates a high potential in the treatment of cancer;however,the majority of studies have been conducted in the pre-clinical,and their clinical applications need further scrutiny.In this review,we describe the biogenesis of EVs,focusing on the effect of MSCs-EVs on CRC cells and CRC-derived EVs on other cells.Furthermore,MSCs-EVs as a drug delivery system for cancers is also reviewed,and perspectives regarding the therapeutic application of MSCs-EVs are discussed.
